Recently Approved and Upcoming Treatments for Narcolepsy.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
19
1
2020
medline:
10
6
2021
entrez:
19
1
2020
Statut:
ppublish
Résumé
Narcolepsy is a chronic, disabling neurologic disorder characterised by excessive daytime sleepiness (EDS) and, in up to 60% of patients, cataplexy. Treatments for narcolepsy are aimed at improving wakefulness (e.g. modafinil, armodafinil, stimulants), reducing cataplexy attacks (e.g. sodium oxybate, venlafaxine), and treating the symptoms of disturbed nocturnal sleep, sleep paralysis and sleep-related hallucinations (e.g. sodium oxybate). In general, medications that increase the release, or inhibit the reuptake, of norepinephrine or dopamine have wake-promoting effects and are useful in managing EDS, whereas medications that inhibit serotonin or norepinephrine reuptake have anticataplectic effects. Modulation of γ-aminobutyric acid B (GABA
Identifiants
pubmed: 31953791
doi: 10.1007/s40263-019-00689-1
pii: 10.1007/s40263-019-00689-1
pmc: PMC6982634
doi:
Substances chimiques
Central Nervous System Stimulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-27Références
Sleep. 2001 May 1;24(3):282-5
pubmed: 11322710
Sleep. 2002 Mar 15;25(2):197-202
pubmed: 11902429
Expert Opin Investig Drugs. 2018 Apr;27(4):389-406
pubmed: 29623725
Br J Pharmacol. 2013 Jun;169(3):632-44
pubmed: 23472741
Sleep Med Rev. 2019 Feb;43:23-36
pubmed: 30503715
J Psychopharmacol. 2018 Dec;32(12):1351-1361
pubmed: 30269642
Ann Neurol. 2019 Mar;85(3):359-370
pubmed: 30694576
Sleep. 2019 Oct 18;:null
pubmed: 31626696
Clin Pharmacokinet. 2000 Dec;39(6):413-27
pubmed: 11192474
Nat Sci Sleep. 2017 Mar 03;9:39-57
pubmed: 28424564
Nat Rev Neurol. 2014 Jul;10(7):386-95
pubmed: 24890646
Sleep Med. 2014 May;15(5):502-7
pubmed: 24780133
Lancet Neurol. 2013 Nov;12(11):1068-75
pubmed: 24107292
J Clin Pharmacol. 2019 Aug;59(8):1120-1129
pubmed: 30865315
Lancet Neurol. 2017 Mar;16(3):200-207
pubmed: 28129985
Int J Neuropsychopharmacol. 2018 Jul 1;21(7):687-696
pubmed: 29635319
Br J Pharmacol. 2011 Jun;163(4):713-21
pubmed: 21615387
J Pharmacol Exp Ther. 2018 Aug;366(2):367-376
pubmed: 29891587
J Pharmacol Exp Ther. 2007 Jan;320(1):365-75
pubmed: 17005916
CNS Drugs. 2017 Oct;31(10):821-834
pubmed: 28940143
Sleep. 2016 Jul 01;39(7):1379-87
pubmed: 27166238
Sleep. 2019 Nov 06;:null
pubmed: 31691827
Sleep. 2019 Oct 21;42(11):null
pubmed: 31529094
Neuropharmacology. 2013 Dec;75:533-8
pubmed: 23665355
Sleep. 2016 Jun 01;39(6):1283-92
pubmed: 27091533
Sleep Med. 2017 Jul;35:80-84
pubmed: 28619187
Nat Rev Dis Primers. 2017 Feb 09;3:16100
pubmed: 28179647
Clin Ther. 2019 Feb;41(2):196-204
pubmed: 30598342
J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):636-41
pubmed: 19211597
Drug Des Devel Ther. 2018 Aug 30;12:2665-2675
pubmed: 30214155
Neuroscience. 2016 May 26;323:135-56
pubmed: 26704637
J Sleep Res. 2001 Mar;10(1):75-81
pubmed: 11285058
Behav Brain Res. 2016 Jul 15;308:205-10
pubmed: 27118715